Fragile X Syndrome
Article Sidebar
Publcation metrics
4224 | 1270 | 796 | 2116 | 4461
Main Article Content
Fragile X Syndrome (FXS) is a genetic disease due to a CGG trinucleotide expansion, named full mutation (greater than 200 CGG repeats), in the fragile X mental retardation 1 gene locus Xq27.3; which leads to an hypermethylated region in the gene promoter therefore silencing it and lowering the expression levels of the fragile X mental retardation 1, a protein involved in synaptic plasticity and maturation. Individuals with FXS present with intellectual disability, autism, hyperactivity, long face, large or prominent ears and macroorchidism at puberty and thereafter. Most of the young children with FXS will present with language delay, sensory hyper arousal and anxiety. Girls are less affected than boys, only 25% have intellectual disability. Given the genomic features of the syndrome, there are patients with a number of triplet repeats between 55 and 200, known as premutation carriers. Most carriers have a normal IQ but some have developmental problems. The diagnosis of FXS has evolved from karyotype with special culture medium, to molecular techniques that are more sensitive and specific including PCR and Southern Blot. During the last decade, the advances in the knowledge of FXS, has led to the development of investigations on pharmaceutical management or targeted treatments for FXS. Minocycline and sertraline have shown efficacy in children.
- Fragile X Syndrome
- FMRP
- intellectual disability
- full mutation
Martin JP, Bell J. A pedigree of mental defect showing sex-linkage. J Neurol Psychiatry. 1943;6(3-4):154–7. DOI: https://doi.org/10.1136/jnnp.6.3-4.154
Hagerman RJ, Hagerman PJ. Fragile X Syndrome. 3. Baltimore: The John Hopkins University Press; 2002. DOI: https://doi.org/10.56021/9780801868436
Bagni C, Tassone F, Neri G, Hagerman R. Fragile X syndrome: Causes, diagnosis, mechanisms, and therapeutics. J Clin Invest. 2012;122(12):4314–22. DOI: https://doi.org/10.1172/JCI63141
Liu Y, Winarni T, Zhang L, Tassone F, Hagerman R. Fragile X-associated tremor/ataxia syndrome (FXTAS) in grey zone carriers. Clin Genet. 2013;84:74–7. DOI: https://doi.org/10.1111/cge.12026
Hall D, Tassone F, Klepitskaya O, Leehey M. Fragile X associated tremor ataxia syndrome in FMR1 gray zone allele carriers. Mov Disord. 2012;27(2):296–300. DOI: https://doi.org/10.1002/mds.24021
Coffee B, Keith K, Albizua I, Malone T, Mowrey J, Sherman SL, et al. Incidence of Fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet. 2009;85:503–14. DOI: https://doi.org/10.1016/j.ajhg.2009.09.007
Hirst MC, Knight SJ, Christodoulou Z, Grewal PK, Fryns JP, Davies KE. Origins of the fragile X syndrome mutation. J Med Genet. 1993;30(8):647–50. DOI: https://doi.org/10.1136/jmg.30.8.647
Gardeazabal AG. El divino. Bogota: Plaza Janes; 1986.
Payan C, Saldarriaga W, Isaza C, Alzate A. Estudio foco endémico de retardo mental en Ricaurte Valle. Acta Biológica Colombiana. 2001;6(2):88.
Hagerman R, Hagerman P. Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome. Lancet Neurol. 2013;12(8):786–98. DOI: https://doi.org/10.1016/S1474-4422(13)70125-X
Fernandez-Carvajal I, Walichiewicz P, Xiaosen X, Pan R, Hagerman PJ, Tassone F. Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. J Mol Diagn. 2009;11(4):324–9. DOI: https://doi.org/10.2353/jmoldx.2009.080173
Tassone F, Iong KP, Tong TH, Lo J, Gane LW, Berry-Kravis E, et al. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med. 2012;4(12):1–113. DOI: https://doi.org/10.1186/gm401
Center for Disease Control and Prevention. Fragile X syndrome (FXS). Accessed: 20 November 2014. Available from:urihttp://www.cdc.gov/ncbddd/fxs/index.htmlhttp://www.cdc.gov/ncbddd/fxs/index.html.
Pietrobono R, Tabolacci E, Zalfa F, Zito I, Terracciano A, Moscato U, et al. Molecular dissection of the events leading to inactivation of the FMR1 gene. Hum Mol Genet. 2005;14(2):267–7. DOI: https://doi.org/10.1093/hmg/ddi024
Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA, Caskey CT, et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell. 1991;66(4):817–22. DOI: https://doi.org/10.1016/0092-8674(91)90125-I
Naumann A, Hochstein N, Weber S, Fanning E, Doerfler W. A distinct DNA-methylation boundary in the 5'-upstream sequence of the FMR1 promoter binds nuclear proteins and is lost in fragile X syndrome. Am J Hum Genet. 2009;85(5):606–16. DOI: https://doi.org/10.1016/j.ajhg.2009.09.018
Stöger R, Kajimura TM, Brown WT, Laird CD. Epigenetic variation illustrated by DNA methylation patterns of the fragile-X gene FMR1. Hum Mol Genet. 1997;6(11):1791–801. DOI: https://doi.org/10.1093/hmg/6.11.1791
Malter HE, Iber JC, Willemsen R, de Graaff E, Tarleton JC, Leisti J, et al. Characterization of the full fragile X syndrome mutation in fetal gametes. Nat Genet. 1997;15(2):165–9. DOI: https://doi.org/10.1038/ng0297-165
Sutcliffe JS, Nelson DL, Zhang F, Pieretti M, Caskey CT, Saxe D, et al. DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet. 1992;1(6):397–400. DOI: https://doi.org/10.1093/hmg/1.6.397
Kniffin CL, Jackson JF. Fragile x mental retardation syndrome. Accessed: 20 November 2014. Available from:urihttp://omim.org/clinicalSynopsis/300624?search=fragile x highlight=x fragilehttp://omim.org/clinicalSynopsis/300624?search=fragile x highlight=x fragile.
Siomi H, Siomi MC, Nussbaum RL, Dreyfuss G. The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein. Cell. 1993;74(2):291–8. DOI: https://doi.org/10.1016/0092-8674(93)90420-U
Ashley CT, Wilkinson KD, Reines D, Warren ST. FMR1 protein: conserved RNP family domains and selective RNA binding. Science. 1993;262(5133):563–6. DOI: https://doi.org/10.1126/science.7692601
Darnell JC, Van Driesche SJ, Zhang C, Hung KYS, Mele A, Fraser CE, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell. 2011;146(2):247–61. DOI: https://doi.org/10.1016/j.cell.2011.06.013
Brown V, Jin P, Ceman S, Darnell JC, O'Donnell WT, Tenenbaum SA, et al. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell. 2001;107(4):477–87. DOI: https://doi.org/10.1016/S0092-8674(01)00568-2
Chen L, Yun SW, Seto J, Liu W, Toth M. The fragile X mental retardation protein binds and regulates a novel class of mRNAs containing U rich target sequences. Neuroscience. 2003;120(4):1005–17. DOI: https://doi.org/10.1016/S0306-4522(03)00406-8
Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004;27(7):370–7. DOI: https://doi.org/10.1016/j.tins.2004.04.009
Gatto CL, Broadie K. Genetic controls balancing excitatory and inhibitory synaptogenesis in neurodevelopmental disorder models. Front Synaptic Neurosci. 2010;2:4. DOI: https://doi.org/10.3389/fnsyn.2010.00004
Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991;65(5):905–14. DOI: https://doi.org/10.1016/0092-8674(91)90397-H
Yrigollen CM, Martorell L, Durbin-Johnson B, Naudo M, Genoves J, Murgia A, et al. AGG interruptions and maternal age affect FMR1 CGG repeat allele stability during transmission. J Neurodev Disord. 2014;6(1):1–11. DOI: https://doi.org/10.1186/1866-1955-6-24
Yrigollen CM, Durbin-Johnson B, Gane L, Nelson DL, Hagerman R, Hagerman PJ, et al. AGG interruptions within the maternal FMR1 gene reduce the risk of offspring with fragile X syndrome. Genetics Med. 2012;14(8):729–36. DOI: https://doi.org/10.1038/gim.2012.34
Fernandez-Carvajal I, Lopez Posadas B, Pan R, Raske C, Hagerman PJ, Tassone F. Expansion of an FMR1 grey-zone allele to a full mutation in two generations. J Mol Diagn. 2009;11(4):306–10. DOI: https://doi.org/10.2353/jmoldx.2009.080174
Nolin SL, Brown WT, Glicksman A, Houck GE, Gargano AD, Sullivan A, et al. Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. Am J Hum Genet. 2003;72(2):454–64. DOI: https://doi.org/10.1086/367713
Berry-Kravis E, Abrams L, Coffey SM, Hall DA, Greco C, Gane LW, et al. Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. Mov Disord. 2007;22(14):2018–30. DOI: https://doi.org/10.1002/mds.21493
Seltzer MM, Baker MW, Hong J, Maenner M, Greenberg J, Mandel D. Prevalence of CGG expansions of the FMR1 gene in a US population-based sample. Am J Med Genet B Neuropsychiatr Genet. 2012;159B(5):589–97. DOI: https://doi.org/10.1002/ajmg.b.32065
Bourgeois JA, Cogswell JB, Hessl D, Zhang L, Ono MY, Tassone F, et al. Cognitive, anxiety and mood disorders in the fragile X-associated tremor/ataxia syndrome. Gen Hosp Psychiatry. 2007;29(4):349–56. DOI: https://doi.org/10.1016/j.genhosppsych.2007.03.003
Martin JR, Arici A. Fragile X and reproduction. Curr Opin Obstet Gynecol. 2008;20(3):216–20. DOI: https://doi.org/10.1097/GCO.0b013e3282fe7254
Filipovic-Sadic S, Sah S, Chen L, Krosting J, Sekinger E, Zhang W, et al. A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome. Clin Chem. 2010;56:399–408. DOI: https://doi.org/10.1373/clinchem.2009.136101
Tassone F, Pan R, Amiri K, Taylor AK, Hagerman PJ. A rapid polymerase chain reaction based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. J Mol Diagn. 2008;10:43–9. DOI: https://doi.org/10.2353/jmoldx.2008.070073
Chen L, Hadd A, Sah S, Filipovic-Sadic S, Krosting J, Sekinger E, et al. An information-rich CGG repeat primed PCR that detects the full range of fragile X expanded alleles and minimizes the need for southern blot analysis. J Mol Diagn. 2010;12:589–600. DOI: https://doi.org/10.2353/jmoldx.2010.090227
Firth HV, Hurst JA, Hall JG. Oxford Desk Reference? Oxford: Oxford University Press; 2005.
O'Neil MJF, Jackson JF. SOTOS SYNDROME 1 SOTOS1. Accessed: 20 November 2014. Available from:urihttp://omim.org/clinicalSynopsis/117550?search=highlight=sotoshttp://omim.org/clinicalSynopsis/117550?search=highlight=sotos.
Hamosh A, Jackson JF. PRADER-WILLI SYNDROME PWS. accessed: 20 November 2014. Available from:urihttp://omim.org/clinicalSynopsis/176270?search=prader highlight=praderhttp://omim.org/clinicalSynopsis/176270?search=prader highlight=prader.
Rueda JR, Ballesteros J, Guillen V, Tejada MI, Solà I. Folic acid for fragile X syndrome. Cochrane database Syst Rev. 2011;(5):CD008476. DOI: https://doi.org/10.1002/14651858.CD008476.pub2
Detich N, Bovenzi V, Szyf M. Valproate induces replication-independent active DNA demethylation. J Biol Chem. 2003;278(30):27586–92. DOI: https://doi.org/10.1074/jbc.M303740200
Tabolacci E, De Pascalis I, Accadia M, Terracciano A, Moscato U, Chiurazzi P, et al. Modest reactivation of the mutant FMR1 gene by valproic acid is accompanied by histone modifications but not DNA demethylation. Pharmacogenet Genomics. 2008;18(8):738–41. DOI: https://doi.org/10.1097/FPC.0b013e32830500a1
Torrioli M, Vernacotola S, Setini C, Bevilacqua F, Martinelli D, Snape M, et al. Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys. Am J Med Genet A. 2010;152A(6):1420–7. DOI: https://doi.org/10.1002/ajmg.a.33484
Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, et al. Advances in the treatment of fragile X syndrome. Pediatrics. 2009;123(1):378–90. DOI: https://doi.org/10.1542/peds.2008-0317
Wirojanan J, Jacquemont S, Diaz R, Bacalman S, Anders TF, Hagerman RJ, et al. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med. 2009;5:145–50. DOI: https://doi.org/10.5664/jcsm.27443
Su T, Fan H-X, Jiang T, Sun W-W, Den W-Y, Gao M-M, et al. Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome. Psychopharmacology. 2011;215(2):291–300. DOI: https://doi.org/10.1007/s00213-010-2130-2
Dziembowska M, Pretto DI, Janusz A, Kaczmarek L, Leigh MJ, Gabriel N, et al. High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am J Med Genet A. 2013;161A(8):1897–903. DOI: https://doi.org/10.1002/ajmg.a.36023
Bilousova T V, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet. 2009;46(2):94–102. DOI: https://doi.org/10.1136/jmg.2008.061796
Wilczynski GM, Konopacki FA, Wilczek E, Lasiecka Z, Gorlewicz A, Michaluk P, et al. Important role of matrix metalloproteinase 9 in epileptogenesis. J Cell Biol. 2008;180(5):1021–35. DOI: https://doi.org/10.1083/jcb.200708213
Wang X, Bozdagi O, Nikitczuk JS, Zhai ZW, Zhou Q, Huntley GW. Extracellular proteolysis by matrix metalloproteinase-9 drives dendritic spine enlargement and long-term potentiation coordinately. Proc Natl Acad Sci U S A. 2008;105(49):19520–5. DOI: https://doi.org/10.1073/pnas.0807248105
Dziembowska M, Milek J, Janusz A, Rejmak E, Romanowska E, Gorkiewicz T, et al. Activity-dependent local translation of matrix metalloproteinase-9. J Neurosci. 2012;32(42):14538–47. DOI: https://doi.org/10.1523/JNEUROSCI.6028-11.2012
Leigh MJS, Nguyen D V, Mu Y, Winarni TI, Schneider A, Chechi T, et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome. J Dev Behav Pediatr. 2013;34(3):147–55. DOI: https://doi.org/10.1097/DBP.0b013e318287cd17
Indah Winarni T, Chonchaiya W, Adams E, Au J, Mu Y, Rivera SM, et al. Sertraline may improve language developmental trajectory in young children with fragile X syndrome: A retrospective chart review. Autism Res Treat. 2012; 2012: 104317. DOI: https://doi.org/10.1155/2012/104317
Moskowitz LJ, Carr EG, Durand VM. Behavioral intervention for problem behavior in children with fragile X syndrome. Am J Intellect Dev Disabil. 2011;116(6):457–78. DOI: https://doi.org/10.1352/1944-7558-116.6.457
Turk J. Fragile X syndrome: lifespan developmental implications for those without as well as with intellectual disability. Curr Opin Psychiatry. 2011;24(5):387. DOI: https://doi.org/10.1097/YCO.0b013e328349bb77
Dew-Hughes D. Educating children with fragile X syndrome. Florence: Routledge; 2003. DOI: https://doi.org/10.4324/9780203561539
Dyer-Friedman J, Glaser B, Hessl D, Johnston C, Huffman LC, Taylor A, et al. Genetic and environmental influences on the cognitive outcomes of children with fragile X syndrome. J Am Acad Child Adolesc Psychiatry. 2002;41(3):237–44. DOI: https://doi.org/10.1097/00004583-200203000-00002
Hessl D, Dyer-Friedman J, Glaser B, Wisbeck J, Barajas RG, Taylor A, et al. The influence of environmental and genetic factors on behavior problems and autistic symptoms in boys and girls with fragile X syndrome. Pediatrics. 2001;108(5):E88. DOI: https://doi.org/10.1542/peds.108.5.e88
Downloads
- David O. Acero-Garcés, Wilmar Saldarriaga, Ana M. Cabal-Herrera, Christian A. Rojas, Randi J. Hagerman, Fragile X syndrome in children , Colombia Medica: Vol. 54 No. 2 (2023)
- Harry Mauricio Pachajoa, Wilmar Saldarriaga, Carolina Isaza, 18p- syndrome: Presentation of two cases with alobar holoprosencenphaly , Colombia Medica: Vol. 41 No. 4 (2010)
- Wilmar Saldarriaga, Carolina Isaza, Presentación de 4 casos de defectos de blastogénesis: complejo cuerpo extremidad, complejo oeis y cordón corto. , Colombia Medica: Vol. 36 No. 3 (2005)
- Carolina Isaza, Wilmar Saldarriaga, Harry Pachajoa, Inadequate use of misoprostol. A public health problem?. , Colombia Medica: Vol. 39 No. 2.Supl.2 (2008): Citogenética
- Harry Mauricio Pachajoa, Carolina Isaza, Carolina Vargas, Wilmar Saldarriaga, Williams-Beuren syndrome: Report of two cases with molecular diagnosis , Colombia Medica: Vol. 42 No. 4 (2011)
- Armicson Felipe Solano, Wilmar Saldarriaga, Carolina Isaza, Pierpaolo Mastroiacovo, Eduardo E. Castilla, Sirenomelia’s cluster in Cali, Colombia. Report of 4 cases in Hospital Universitario del Valle in 54 days. , Colombia Medica: Vol. 37 No. 3 (2006)
- Harry Pachajoa, Katherine Tabares, Juan Carlos Quintero, Wilmar Saldarriaga, Carolina Isaza, Prenatal diagnosis of cyclopia associated to trisomy 13. , Colombia Medica: Vol. 39 No. 1 (2008)
- Martha Lucía Montes, Wilmar Saldarriaga, Carolina Isaza, Description of a case of Cornelia de Lange syndrome. Contribution to better ante-natal and post-natal diagnoses. , Colombia Medica: Vol. 37 No. 4 (2006)
- Ana María Monsalve, Isabel Cristina Londoño, Javier Ocampo, Diego Fernando Cruz, Wilmar Saldarriaga, Carolina Isaza, Geographical distribution of congenital malformations at Hospital Universitario del Valle, Santiago de Cali, Colombia, March of 2004-February of 2005. , Colombia Medica: Vol. 38 No. 1 (2007)
- Harry Pachajoa, Wilmar Saldarriaga, Carolina Isaza, Gastroschisis at hospital of third level in Cali, Colombia, from March 2004 to February 2006. , Colombia Medica: Vol. 39 No. 2.Supl.2 (2008): Citogenética
Similar Articles
- David O. Acero-Garcés, Wilmar Saldarriaga, Ana M. Cabal-Herrera, Christian A. Rojas, Randi J. Hagerman, Fragile X syndrome in children , Colombia Medica: Vol. 54 No. 2 (2023)
You may also start an advanced similarity search for this article.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use